Atara (ATRA) news
Recent news
Atara's Tablelcleucel BLA resubmitted to FDA
AInvest Wire · Sep 30, 2026Atara Biotherapeutics reports that the Tabelecleucel biologics license application has been resubmitted to the U.S. Food and Drug Administration
Atara Biotherapeutics, Inc. (Nasdaq: ATRA) announced that Pierre Fabre Pharmaceuticals, Inc. (PFP), the U.S. subsidiary of Pierre Fabre Laboratories, has engaged in discussions with the U.S. Food and Drug Administration (FDA) following the receipt of a Complete Response Letter (CRL) for the…
AInvest Wire · Sep 30, 2026Atara Bio 2Q loss/share 32c vs. EPS 19c y/y
Atara Biotherapeutics (NASDAQ: ATRA) reported a net loss of $0.32 per share for the second quarter of 2025, compared to net income of $0.19 per share in the same period of 2024. The company’s financial performance reflects a significant shift from profitability to a loss, driven primarily by the…
AInvest Wire · Aug 12, 2026US FDA puts clinical hold on Atara's trials for cancer cell therapies
US FDA puts clinical hold on Atara's trials for cancer cell therapies The US Food and Drug Administration (FDA) has issued a complete response letter (CRL) to Atara Biotherapeutics, a leading biotechnology company specializing in T-cell immunotherapy, regarding the Biologics License Application…
AInvest Wire · Jan 21, 2025ImportantAtara Biotherapeutics shares up 20% premarket after Co. announces board appointment and capital raise
Atara Biotherapeutics shares up 20% premarket after Co. announces board appointment and capital raise Atara Biotherapeutics, Inc. (ATRA) experienced a significant surge in its stock price by 20% during pre-market hours on October 3, 2024. The biotechnology company announced a board appointment and…
AInvest Wire · Sep 4, 2024Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.